As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to own the patient journey.
|Articles|September 1, 2008
- Pharmaceutical Executive-09-01-2008
- Volume 0
- Issue 0
Industry Audit + Company of the Year 2008
Author(s)Bill Trombetta
Pharm Exec's 7th annual review of the top companies. We slice and dice the numbers to see who's the best a what. (pdf)
Advertisement
Articles in this issue
about 18 years ago
The New Codeabout 18 years ago
Publish or Perishabout 18 years ago
How Do You Solve a Problem Like Manufacturing?about 18 years ago
Foreign Affairsabout 18 years ago
Tapping the Fountabout 18 years ago
The M&A Numbersabout 18 years ago
The Salesforce Software Shiftabout 18 years ago
Unleash the Dragon 2about 18 years ago
Place Your Betsabout 18 years ago
The Orphan OpportunityAdvertisement
Related to this article
Life sciences liability risks change character — not just size — as companies move from R&D to commercialization.
How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.
Bristol Myers Squibb’s Wendy Short Bartie on recasting corporate affairs as an enterprise value engine that connects trust, access and the patient voice.
A new benchmarking survey of 33 biotech and medtech leaders reveals a leadership community operating in crisis mode — and what that means for how the industry needs to rethink peer support, advisory and the isolation built intothe CEO role itself.
Advertisement
Advertisement
Trending on PharmExec
1
CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
2
Roundup: AbbVie & Iambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM
3
Pharmaceutical Executive Daily: AbbVie Forms Ai-Powered Drug Discovery Partnership with Iambic
4
How Clinical Data Layers Impact How Patient Availability is Determined
5